Immune System Key

Drug Development for Malignant and Autoimmune Diseases

Active Seed Startup Jerusalem Founded 1992-02

Immune System Key (ISK) is engaged in the discovery and development of treatments for malignant cancers and autoimmune diseases, with a primary focus on treating patients with acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer. Its assets are based on novel human-secreted peptides that were discovered by the company's founder…

SectorHealth Tech & Life Sciences
StageSeed
Total raised$3.7M
Employees2
Founded1992-02
HQJerusalem
Patents1
Confidence90
Sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & Development
Technology
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProviders